ChemoCentryx, Inc. (CCXI)
| Market Cap | 2.54B |
| Revenue (ttm) | 34.27M |
| Net Income (ttm) | -121.10M |
| Shares Out | 70.03M |
| EPS (ttm) | -1.74 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,115,190 |
| Open | 39.38 |
| Previous Close | 38.88 |
| Day's Range | 35.68 - 38.95 |
| 52-Week Range | 9.53 - 70.29 |
| Beta | 1.83 |
| Analysts | Buy |
| Price Target | 71.38 (+96.7%) |
| Earnings Date | Nov 9, 2021 |
About CCXI
ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It develops Avacopan, an orally administered selective complement 5a receptor inhibitor for the treatment of anti-neutrophil cytoplasmic autoantibody-associated vasculitis; and completed Phase II clinical trial for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy. The...
Financial Performance
In 2020, ChemoCentryx's revenue was $64.89 million, an increase of 79.61% compared to the previous year's $36.13 million. Losses were -$55.36 million, -0.24% less than in 2019.
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for ChemoCentryx stock is "Buy." The 12-month stock price forecast is 71.38, which is an increase of 96.75% from the latest price.
News
ChemoCentryx (CCXI) Gets Positive CHMP Opinion for Tavneos
ChemoCentryx (CCXI) receives a positive recommendation from the CHMP for its lead drug Tavneos to treat two forms of ANCA-associated vasculitis.
Positive Recommendation for Use of TAVNEOS™ (avacopan) in ANCA Vasculitis Adopted by European Medicines Agency (EMA) ...
SAN CARLOS, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP)...
ChemoCentryx (CCXI) Q3 Loss Narrower Than Expected, Sales Top
ChemoCentryx (CCXI) posts narrower-than-expected loss for third-quarter 2021. The company's revenues for the quarter also beat estimates.
ChemoCentryx to Participate in Two Upcoming Investor Conferences
SAN CARLOS, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will participate in two upc...
Big Pharma Is Going Holiday Shopping. Who's Next?
After an infusion of cash from COVID-19 treatments, many companies are on the lookout for acquisitions.
ChemoCentryx (CCXI) Reports Q3 Loss, Tops Revenue Estimates
ChemoCentryx (CCXI) delivered earnings and revenue surprises of 30.44% and 20.70%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Should You Buy ChemoCentryx (CCXI) Ahead of Earnings?
ChemoCentryx (CCXI) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Abstracts at the Annual Meetings of the American Society of Nephrology and American College of Rheumatology Highlight...
SAN CARLOS, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced the abstracts accepted for presentation and publication as part of the annual meetings of the Am...
ChemoCentryx to Hold Third Quarter 2021 Financial Results Conference Call on Tuesday, November 9, 2021
MOUNTAIN VIEW, Calif., Nov. 02, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's third quarter 2021 financial results will be released after market close o...
ChemoCentryx (CCXI) Expected to Beat Earnings Estimates: Should You Buy?
ChemoCentryx (CCXI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's Next For ChemoCentryx Stock After Over A 100% Rise In A Month?
The stock price of ChemoCentryx, a biopharmaceuticals company focused on orally-administered therapeutics to treat autoimmune diseases and inflammatory disorders, has skyrocketed with a 104% rise over t...
3 Biotech Stocks That Could Rise 90% or More, According to Wall Street
These stocks are expected to put up big gains in a short amount of time.
Is It Too Late to Buy ChemoCentryx Stock?
The stock surged after obtaining FDA approval for avacopan.
Amber Specialty Pharmacy Selected by ChemoCentryx to Dispense TAVNEOS™ (avacopan), an Adjunctive Treatment for ANCA-A...
OMAHA, Neb.--(BUSINESS WIRE)--Amber Specialty Pharmacy announces that it will begin dispensing TAVNEOS™ (avacopan), a first of its kind orally-administered selective complement 5a receptor inhibitor, as...
2 Super-Charged Growth Stocks to Buy Now
These two small drugmakers are poised for a long-winded growth spurt.
BZ Chart Of The Day: ChemoCentryx
There's an old saying on Wall Street that "gaps refill." It's true and it may be about to happen to shares of ChemoCentryx, Inc. (NASDAQ:CCXI).
ChemoCentryx Appoints Rita I. Jain, M.D.
Appointment Brings More than 20 Years of Drug Development Experience as Company Launches First Product
Why ChemoCentryx Stock Skyrocketed Today
Investors are excited about the biotech's game-changing new drug.
Should you buy ChemoCentryx stock as shares spike 70% on avacopan approval?
On Friday, ChemoCentryx Inc. (NASDAQ:CCXI) shares spiked nearly 70% after announcing the Food and Drug Administration (FDA) had approved avacopan for the treatment of ANCA vasculitis. Avacopan is an ora...
ChemoCentryx (CCXI) Tavneos Gets FDA Nod for ANCA Vasculitis
The FDA approves ChemoCentryx's (CCXI) lead drug Tavneos to treat ANCA-associated vasculitis. It is the company's first drug to get FDA approval.
ChemoCentryx, Allogene Show the Risks and Rewards of Nasdaq Biotech Stocks
The broader market was mixed on Friday.
CCXI Stock: The Big FDA News That Has ChemoCentryx Shares Skyrocketing 60%
CCXI stock is making its investors very happy this morning with some huge gains. It's receiving FDA approval for a rare disease treatment.
Here's why ChemoCentryx is up 50% on Friday morning
ChemoCentryx Inc (NASDAQ: CCXI) shareholders had every reason to be happy about on Friday morning. The shares of the group traded higher on Friday morning, thanks to the announcement made by the group.
ChemoCentryx (CCXI) Soars 5.4%: Is Further Upside Left in the Stock?
ChemoCentryx (CCXI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength...
Why Did ChemoCentryx Shares Soar 70% On Friday Premarket?
The FDA has approved ChemoCentryx Inc's (NASDAQ: CCXI) Tavneos (avacopan) as an adjunctive treatment for anti-neutrophil cytoplasmic autoantibody-associated vasculitis (ANCA-associated vasculitis or ANC...